tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Nathan Weinstein, 34 are a BUY (94.44%), 2 are a HOLD (5.56%).
Analyst Nathan Weinstein, currently employed at AEGIS, carries an average stock price target met ratio of 8.33% that have a potential upside of 6.85% achieved within 21 days.
Nathan Weinstein’s has documented 64 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on EVGN, Evogene at 12-Sep-2022.
Analyst best performing recommendations are on ORMP (ORAMED PHARMACEUTICALS).
The best stock recommendation documented was for ORMP (ORAMED PHARMACEUTICALS) at 6/8/2021. The price target of $20 was fulfilled within 62 days with a profit of $6.15 (44.4%) receiving and performance score of 7.16.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$15
$13.59 (963.83%)
$15
2 months 15 days ago
(30-Aug-2024)
0/6 (0%)
$13.7 (1053.85%)
Buy
$9
$7.59 (538.30%)
1 years 6 months 2 days ago
(12-May-2023)
0/3 (0%)
$7.1 (373.68%)
Buy
1 years 7 months 18 days ago
(27-Mar-2023)
0/1 (0%)
$17.08 (114.48%)
Buy
$28
2 years 7 months 13 days ago
(01-Apr-2022)
0/2 (0%)
$16.83 (150.67%)
Hold
$9
$7.59 (538.30%)
$17
2 years 7 months 14 days ago
(31-Mar-2022)
0/3 (0%)
$3.91 (76.82%)
What Year was the first public recommendation made by Nathan Weinstein?
